Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHANE M DRAHOS

Allopathic & Osteopathic Physicians Family Medicine Sleep Medicine

NPI
1952780934
CMS profile
2880500
Location
WINTER GARDEN, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$80,810.61

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHANE M DRAHOS

NPI 1952780934 · CMS profile ID 2880500

Allopathic & Osteopathic Physicians / Family Medicine / Sleep Medicine

WINTER GARDEN, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952780934?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952780934?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952780934?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1952780934?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $80,810.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $6,120.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234298338 CMS
JAZZ PHARMACEUTICALS INC. $245.7604/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234302445 CMS
JAZZ PHARMACEUTICALS INC. $28.7204/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234324059 CMS
JAZZ PHARMACEUTICALS INC. $22.6704/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234332959 CMS
JAZZ PHARMACEUTICALS INC. $2,040.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299916 CMS
JAZZ PHARMACEUTICALS INC. $126.2504/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234305938 CMS
JAZZ PHARMACEUTICALS INC. $24.3804/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234330529 CMS
JAZZ PHARMACEUTICALS INC. $448.1704/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301463 CMS
JAZZ PHARMACEUTICALS INC. $448.1704/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301465 CMS
JAZZ PHARMACEUTICALS INC. $144.0003/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234304849 CMS
JAZZ PHARMACEUTICALS INC. $144.0003/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234304851 CMS
JAZZ PHARMACEUTICALS INC. $287.0403/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234302189 CMS
JAZZ PHARMACEUTICALS INC. $30.3803/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234321935 CMS
JAZZ PHARMACEUTICALS INC. $6,630.0003/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234298218 CMS
JAZZ PHARMACEUTICALS INC. $765.0003/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234300755 CMS
JAZZ PHARMACEUTICALS INC. $212.3503/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234302715 CMS
JAZZ PHARMACEUTICALS INC. $124.9603/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234306324 CMS
JAZZ PHARMACEUTICALS INC. $3,315.0003/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299400 CMS
JAZZ PHARMACEUTICALS INC. $122.4403/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234306824 CMS
Avadel CNS Pharmaceuticals, LLC $17.3303/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208533584 CMS
JAZZ PHARMACEUTICALS INC. $27.8102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234325311 CMS
JAZZ PHARMACEUTICALS INC. $3,570.0002/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299216 CMS
JAZZ PHARMACEUTICALS INC. $2,040.0002/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299914 CMS
JAZZ PHARMACEUTICALS INC. $593.8802/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301125 CMS
JAZZ PHARMACEUTICALS INC. $404.7102/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301581 CMS
JAZZ PHARMACEUTICALS INC. $266.9302/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234302309 CMS
JAZZ PHARMACEUTICALS INC. $125.9802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234305974 CMS
JAZZ PHARMACEUTICALS INC. $45.1602/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234313713 CMS
JAZZ PHARMACEUTICALS INC. $21.4002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234334875 CMS
JAZZ PHARMACEUTICALS INC. $14.7002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234344457 CMS
JAZZ PHARMACEUTICALS INC. $12.1902/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234346027 CMS
JAZZ PHARMACEUTICALS INC. $25.6202/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234328248 CMS
JAZZ PHARMACEUTICALS INC. $147.8702/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234304473 CMS
JAZZ PHARMACEUTICALS INC. $147.8402/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234304475 CMS
JAZZ PHARMACEUTICALS INC. $3,570.0002/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234299222 CMS
JAZZ PHARMACEUTICALS INC. $1,530.0002/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234300156 CMS
JAZZ PHARMACEUTICALS INC. $1,530.0002/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234300158 CMS
JAZZ PHARMACEUTICALS INC. $399.9901/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301603 CMS
JAZZ PHARMACEUTICALS INC. $399.9801/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301605 CMS
JAZZ PHARMACEUTICALS INC. $424.4101/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301521 CMS
JAZZ PHARMACEUTICALS INC. $47.0001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234313553 CMS
JAZZ PHARMACEUTICALS INC. $31.0001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234321343 CMS
JAZZ PHARMACEUTICALS INC. $24.0001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234331033 CMS
JAZZ PHARMACEUTICALS INC. $642.3501/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234301039 CMS
JAZZ PHARMACEUTICALS INC. $150.0001/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234304035 CMS
JAZZ PHARMACEUTICALS INC. $12.3201/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234345985 CMS
JAZZ PHARMACEUTICALS INC. $122.0101/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234307006 CMS
JAZZ PHARMACEUTICALS INC. $122.0101/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234307008 CMS
JAZZ PHARMACEUTICALS INC. $121.9901/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234307012 CMS
JAZZ PHARMACEUTICALS INC. $8,160.0001/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234298032 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.17 2
PY2020 $117.95 3
PY2021 $184.80 7
PY2022 $47,483.58 69
PY2023 $91,128.22 208
PY2024 $97,154.93 99
PY2025 $80,810.61 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $117,602.15 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,903.18 11/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074346
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 08/30/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074392
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 08/27/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074332
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,250.80 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074312
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074314
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,644.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074316
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074318
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074320
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074322
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074324
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074326
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,250.80 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074328
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074330
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074336
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074338
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074342
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074344
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $400.00 07/10/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074334
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $835.90 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074308
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $708.50 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074310
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $824.98 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074340
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 07/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074388
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 07/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074390
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.00 06/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074296
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,100.00 06/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074306
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $65.91 06/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074304
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,692.52 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074278
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074298
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074300
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,438.50 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074280
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074282
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $708.50 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074284
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074286
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,002.30 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074288
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $835.90 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074290
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 05/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074384
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 05/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074386
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/12/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074292
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 04/12/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074294
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,002.30 04/01/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074302
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.75 03/29/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074372
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 03/29/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074374
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $389.09 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074266
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $902.07 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074268
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074270
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074276
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,550.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074248
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074250
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074252
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074254
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074256
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,059.70 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074258
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,094.65 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074260
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074262
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074264
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074272
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $993.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074274
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074348
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074350
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.90 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074352
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.96 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074354
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.84 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074356
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074358
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11.52 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074360
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074362
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $20.88 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074364
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074366
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074368
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074370
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $91.22 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074376
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $356.10 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074378
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $306.72 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074380
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074382